BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12397466)

  • 1. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
    Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
    Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies.
    Macfarlane DJ; Durrant S; Bartlett ML; Allison R; Morton AJ
    Nucl Med Commun; 2002 Nov; 23(11):1099-106. PubMed ID: 12411839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
    Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
    Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
    Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
    J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
    Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
    Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
    Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
    J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
    Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
    Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation.
    Pedraza-López M; Ferro-Flores G; de Murphy CA; Tendilla JI; Villanueva-Sánchez O
    Nucl Med Commun; 2004 Jun; 25(6):615-21. PubMed ID: 15167523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
    Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
    Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
    Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
    Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
    Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
    Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.